Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CNK-UT009 (Second Affiliated Hospital of Zhejiang University School of Medicine)
- Development stage
- Unknown
- Lead developer
- ST Phi Therapeutics
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CNK-UT009 is an allogeneic ("universal") chimeric antigen receptor (CAR) T-cell therapy targeting the CD7 antigen. Developed by the Second Affiliated Hospital of Zhejiang University School of Medicine in collaboration with Cure-NK, it is designed to deplete CD7-positive cells, which include both malignant T cells and auto-reactive T cells involved in autoimmune pathogenesis. By eliminating these populations, CNK-UT009 aims to restore immune homeostasis in conditions where the immune microenvironment is imbalanced. The therapy is currently being investigated in clinical trials for difficult-to-treat inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, particularly for patients refractory to multiple biologics. It has also demonstrated preliminary safety and efficacy in patients with steroid-refractory graft-versus-host disease (GVHD), type 1 diabetes mellitus, and certain hematologic malignancies such as acute myeloid leukemia (AML).
- Other names
- Universal CNK-UT009 Cell Injection
02
Targets
BCMA (B-cell maturation antigen)MICB (Major histocompatibility complex class i-related protein B)CD70 (Cluster of Differentiation 70)CD28 (Cluster of Differentiation 28)
Beyond the preview
Go deeper on CNK-UT009 (Second Affiliated Hospital of Zhejiang University School of Medicine).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CNK-UT009 (Second Affiliated Hospital of Zhejiang University School of Medicine).